Soley Therapeutics has raised $200 million in Series C funding to move its cell stress-sensing platform and pipeline into clinical development, including IND-enabling work and trials for two first-in-class, internally discovered oncology programs. The company said proceeds will also support the advancement of non-oncology stress-reducing drug candidates targeting neurodegenerative disorders and metabolic diseases, as well as continued platform scale-up.
Surveyor Capital was the primary investor in the round, joined by new investors HRTG Partners, RWN Management, and others. Existing backers, including the Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investment® LP, also participated, along with other undisclosed investors.
Soley’s platform measures time-resolved cellular responses across thousands of features in human cells and uses computer vision and AI to convert those signals into structured signatures. The company said it can screen hundreds of thousands of compounds per week, generate reproducible data at scale through in-house automation and robotics, and train proprietary AI/ML models to accelerate hit discovery, mechanistic insight generation, and molecule design.
KEY QUOTE:
“We built Soley to measure how living human cells, in health and disease, respond to drug exposure and determine their fate.”“We are thrilled by the strong investor support from life sciences and technology focused funds as we advance our lead programs into the clinic and expand our platform to continue building a first-in-class pipeline.”
Yerem Yeghiazarians, M.D., Co-founder and CEO, Soley Therapeutics
